3282 results about "Mucous membrane" patented technology

Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C8-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).

Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including an antiseptic selected from the group consisting of halogenated phenols, bisphenols, diphenyl ethers, anilides and derivatives thereof, and combinations thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).

Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the alpha -hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one calcitonin gene related peptide ("CGRP") antagonist, e.g., CGRP 8-37 or an anti-CGRP antibody.

The addition of low concentrations of combinations of water-soluble organic salts of zinc to gels, creams, lotions or ointments can increase the ability of these products to reduce or prevent exogenous irritants from causing irritation of the underlying substrate. The addition of low concentrations of combinations of water-soluble organic zinc salts to these gels, creams, lotions or ointments also can reduce the irritation of skin or mucous membranes caused by the addition of potentially-irritating substances such as spermicides, microbicides, fungicides or other therapeutic agents to the gel, cream, lotion or ointment. The advantages of this anti-irritant approach over others, which generally employ high concentrations of single zinc salts, are the reduced potential for zinc toxicity, the reduced potential for toxicity related to zinc itself, and the preservation of the desirable biological properties of potentially-irritating therapeutic substances added to the gel, cream, lotion or ointment.

Tissue dressing assemblies are formed from hydrophilic polymer sponge structures. The tissue dressing assemblies can be used, e.g., (i) stanch, seal, or stabilize a site of tissue injury, tissue trauma, or tissue access; or (ii) form an anti-microbial barrier; or (iii) form an antiviral patch; or (iv) intervene in a bleeding disorder; or (v) release a therapeutic agent; or (vi) treat a mucosal surface; or (vii) combinations thereof. The tissue dressing structures are made compliant, e.g., by (i) micro-fracturing of a substantial portion of the sponge structure by mechanical manipulation prior to use, or (ii) a surface relief pattern formed on a substantial portion of the sponge structure prior to use, or (iii) a pattern of fluid inlet channels formed in a substantial portion of the sponge structure prior to use, or (iv) the impregnation of a sheet material within the sponge structure.

A rod-like or tube-like sphincteric closure device is micro-invasively implanted beneath the surface of the posterior mucosal wall to elevate the mucosa and close the lumen, by using a delivery device operated through the urethra. To initiate voiding, the muscle-rich anterior urethral wall contracts and widens the lumen beyond the closing or elevating range of the sphincteric closure device. For urethral obstruction, repelling magnets are micro-invasively implanted beneath the surface of mucosa with the delivery device through the urethra, to widen the lumen with magnetic force.

Instruments, systems and methods are provided for performing submucosal medical procedures in a desired area of the digestive tract using endoscopy. Instruments include safe access needle injection instruments incorporating electrosurgical capability, a submucosal tunneling instrument, a submucosal dissection instrument, a mucosal resection device and submucosal biopsy system. Systems include a combination of one or more of such instruments with or without injectable agents. Embodiments of various methods for performing the procedures are also provided.

The present invention relates to compositions comprising quaternary ammonium compounds and essential oils or individual constituents thereof which exhibit enhanced antimicrobial effects. Such combinations may be comprised in lotions, gels, creams, soaps, etc. for application to skin or mucous membranes. The invention is based, at least in part, on the observation that synergistic antimicrobial effects are achieved with combinations of essential oils or individual constituents thereof and low concentrations of quaternary ammonium compounds.

A dermal, transdermal, mucosal or transmucosal delivery device includes a backing layer overlying an ingredient containing reservoir, and having a microprotrusion array attached thereto, a cover for the reservoir having at least one opening therethrough, an adhesive layer and a liner layer. Upon removal of the liner layer, the device may be placed over the desired area of the skin or mucosa and adhesively applied thereto allowing the ingredients to flow from the reservoir through the at least one opening to the skin or mucosa.

An endoscopic tissue resection device and related method is used in conjunction with a flexible or rigid endoscope. Tissue is resected by shaving thin layers of tissue for diagnostic and therapeutic purposes.

The present invention includes compositions and methods for the treatment and prevention of oral mucosal disorders and for promotion of bone health. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with anti-inflammatory agents and/or antibacterial agents, to treat oral mucosal disorders and promote bone health. The compositions of the invention are used to prevent and reverse oral mucosal disorders and bone loss (osteopenia and osteoporosis) associated with aging and chronic inflammation. Oral mucosal disorders include Periodontitis, gingivitis and related oral mucosal inflammation. Formulations of the compositions of the invention include capsules, tablets, toothpastes, oral gels, mouthwashes, mouth rinses, lozenges, chewing gum, dental floss, and dental topical formulations, and fortified foods.

The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, by articles such as gloves or condoms, or by various physical, chemical, mechanical, or biological irritants.

A flexible sheath is removably inserted into an instrument-inserting channel of an endoscope. A treating member for applying a treatment to mucous membrane in a body cavity is projected from and withdrawn into the distal end of the sheath by an operation conducted at the proximal end of the sheath. An exposed electrode is provided at the distal end surface of the sheath. An electrically conductive member extending through the sheath is electrically connected at a distal end thereof to the electrode and at a proximal end thereof to a high-frequency power supply at the proximal end of the sheath.

Peptides of general formula (I), their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use for the treatment and/or care of conditions, disorders and/or diseases of the skin and/or mucous membranes.

The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, or by various physical, chemical, mechanical, or biological irritants, including infectious agents.

PCT No. PCT/FI98/00008 Sec. 371 Date Aug. 26, 1999 Sec. 102(e) Date Aug. 26, 1999 PCT Filed Jan. 2, 1998 PCT Pub. No. WO98/29090 PCT Pub. Date Jul. 9, 1998The present invention relates to preparations alleviating the symptoms caused by drying of the mucous membranes of the body. The preparations contain trimethylglycine as an active agent. The invention also relates to the use of trimethylglycine as an agent alleviating the symptoms of dry mucous membranes in different preparations intended for the body care and hygiene, and to a method of alleviating the symptoms, caused by drying, appearing on the mucous membranes of the body.

The present invention relates to methods and compositions for the protection of skin and mucous membranes from undesirable side effects of ionizing radiation in a patient undergoing ionizing radiation therapy. In particular, the application describes compositions and methods comprising the topical use of Nrf2 inducers.

A removable denture system comprising a support beam fixedly attached to the individual's alveolar ridge above the mucous membrane by a plurality of dental implants, and a denture generally conforming with the dental parameters of the individual and integrated with a supper-structure. The supper-structure comprises at least a portion shaped in confirmation with the support beam, and a denture locking arrangement for removably though fixedly articulating the denture to the support beam preventing unintentional disengagement of the denture.

The present invention relates to a method for preparing a radioactive film for local radioactive treatment. More particularly, the present invention relates to a method for preparing a radioactive film comprising the steps of; dissolving 0.1˜14.5 weight % of a stable nuclide and 13˜32.5 weight % of a film-forming base for the total amount of a solvent in the solvent; applying a stable nuclide solution on a release paper by a coater and drying; and irradiating a stable nuclide film with neutrons in a nuclear reactor. A method for preparing a radioactive film according to the present invention provides a radioactive film having a uniform distribution of radionuclides and an even thickness. Therefore, the therapeutic efficacy of the radioactive film for selective treatment of a lesion may be maximized by attaching the radioactive film on a patient's skin or a mucous membrane and by direct radioactive radiation.

Personal care and hygiene formulations for topical application to mucosal surfaces. These formulations include an amphiphilic lipid carrier in the form of a colloidal composition which can include a micellar aggregate or mixed micelles dispersed in a continuous aqueous phase, or an emulsion of lipid droplets suspended in a continuous aqueous phase, and an active agent which is an anti-microbial agent. The lipid carrier has high adhesiveness to mucous membranes such as the soft tissues of the oral cavity. The lipid carrier also has a high load capacity for the active agent to be carried to these tissues. These formulations have the desirable properties of carrying a large amount of active agent for controlled and prolonged release thereof at the desired site, such as mucous membrane surfaces and surrounding tissue. Accordingly, the present invention provides a formulation for oral or topical application including an anti-microbial agent and a lipid. The agent is held by the carrier through a hydrophobic interaction and is released from the carrier in a controlled manner over a prolonged period of time. The lipid is also characterized by having a high adhesive capability towards mucous membrane surfaces. The lipid and the agent are preferably present in a ratio in a range of from about 1:10 to 10:1, more preferably from about 1:5 to about 5:1, and most preferably from about 1:3 to about 3:1 in the formulation.